ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated Incurable Ewing Sarcoma
-
- STATUS
- Recruiting
-
- days left to enroll
- 86
-
- participants needed
- 41
-
- sponsor
- Sarcoma Alliance for Research through Collaboration
Updated on 17 January 2021
SARC Office
Primary Contact
National Cancer Institute (9.7 mi away) Contact
+4 other locationcyclophosphamide
immunosuppressive
measurable disease
cell transplantation
doxorubicin
irinotecan
cancer chemotherapy
temozolomide
ifosfamide
Summary
The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.
Details
| Treatment | Temozolomide, Irinotecan, Niraparib |
|---|---|
| Clinical Study Identifier | NCT02044120 |
| Sponsor | Sarcoma Alliance for Research through Collaboration |
| Last Modified on | 17 January 2021 |
How clear was the trial content above?
Hard
Easy
Adding a note
Select a piece of text and start making personal notes.
Similar trials to consider
Loading...
Browse trials for
cyclophosphamide
immunosuppressive
measurable disease
cell transplantation
doxorubicin
irinotecan
cancer chemotherapy
temozolomide
ifosfamide
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer